SHOULD DISEASE-MODIFYING THERAPY BE STOPPED IN PATIENTS WITH RHEUMATOID ARTHRITIS BEFORE ENDOPROSTHETIC JOINT REPLACEMENT?

SHOULD DISEASE-MODIFYING THERAPY BE STOPPED IN PATIENTS WITH RHEUMATOID ARTHRITIS BEFORE ENDOPROSTHETIC JOINT REPLACEMENT?

Objective: to analyze disease activity, functional state, quality of life (QL), and the frequency of infectious complications in methotrexate (MT) – or leflunomide (LF)-treated patients with rheumatoid arthritis (RA) who had undergone endoprosthetic replacement of the large joints of the lower limbs...

Full description

Saved in:
Bibliographic Details
Main Authors: N. A. Savenkova, V. N. Amirdzhanova, S. A. Makarov, A. L. Logunov, M. A. Makarov, V. V. Kolomatsky, D. V. Goryachev
Format: Article
Language:Russian
Published: IMA PRESS LLC 2011-06-01
Series:Научно-практическая ревматология
Subjects:
rheumatoid arthritis
endoprosthetic joint replacement
methotrexate, leflunomide
infectious complications
Online Access:https://rsp.mediar-press.net/rsp/article/view/1292
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://rsp.mediar-press.net/rsp/article/view/1292

Similar Items